

Analysis of longitudinal *nef* sequence variation throughout HIV-2 infection



M. Remédios¹, E. Paixão², H. Feliciano³, A. Silva-Graça³, E. Pádua¹

¹National Institute of Health, Department of Infectious Diseases, Lisbon/PT, ²National Institute of Health, Department of Epidemiology, Lisbon/PT, ³Hospital Militar de Belém, Unit of Infectious Diseases, Lisbon/PT

Contact e-mails: marta.remédios@insa.min-saude.pt; elizabeth.padua@insa.min-saude.pt

Background

The HIV/AIDS infection is considered a public health problem and both types of virus, HIV-1 and HIV-2, are circulating in Portugal [1]. About 4% of the notified HIV/AIDS cases at the National Surveillance System were diagnosed as HIV-2 infections [2]. Although HIV-2 infection may cause a severe immunodeficiency, lower transmission and disease progression rates were described, compared with HIV-1 infection [3,4].

The *nef* gene encodes for a multifunctional protein. *Nef* sequence motifs were associated with several viral processes: down-regulation of CD4, CD3, CD28, MHC-I and MHC-II molecules, interference with intracellular signalling and apoptotic pathways, and increase of replication and virion infectivity [5,6]. The role of *Nef* protein during the development of AIDS has been clearly demonstrated in simian immunodeficiency virus model [7]. However, determinants which play a part in the pathogenesis of HIV-1 are relatively poorly understood, and even less is known about this protein and the HIV-2 infection.

Objectives

To analyze the *nef* gene sequence variation throughout HIV-2 infection, including the *Nef* functional motifs, from infected-individuals in different clinical stages of infection, in order to establish an association between the reconstruction of mutated sequences and/or motifs with the progression of infection.

Results

Characterization of the HIV-2 Population (Table 1)

- A total of 17 HIV-2 infected individuals, with a time of infection range from 2 to 34 years, were enrolled in the study: 6 (35%) were male and 11 (65%) were female. A minimum of 2 and a maximum of 9 blood samples were studied for each individual and collected with an interval time from 2 to 88 months.
- Only 2 patients (A and B) were at AIDS clinical stage and 15 were asymptomatic when the first sample was collected; while 12 cases remained asymptomatic during time, 3 patients (C, J, M) have progress to AIDS.
- The majority of subjects have born outside of Portugal (70.5%) and the HIV-2 infection was acquired in African countries (83%), namely Guinea Bissau, Cape Vert and Angola, and mainly by heterosexual contacts (88%).
- All HIV-2 symptomatic cases fulfill antiretroviral therapy. Only 6 asymptomatic individuals were naïve to antiretroviral drugs.
- The mean of CD4 counts was 602.3 ± 332.7 cells/mm³ for asymptomatic group and 173.8 ± 83.6 cell/mm³ for AIDS cases (Mann-Whitney, p<0.001).

Classification and Analysis of HIV-2 *Nef* Sequences

- A total of 48 sequences, classified as HIV-2 *nef* subtype A, were obtained in the study (Figure 1). All sequences encode a *Nef* full-length protein without any deletions or truncations. The tree showed long branches for P2 and J3 sequences but only J3 was hypermutated (p=0.0001) and removed from further analysis (Figure 1).
- A high degree of amino acid conservation in *Nef* sequences was observed in AIDS patients [63%; C. I. of 95% (62 ;63)], comparatively to asymptomatic individuals [19%; C. I. of 95% (18 ;19)] (Table 2).

Table 1 – Epidemiological and clinical data of the HIV-2 infected studied population.

Individual	Gender	Age ¹	Birthplace	Country of Infection	Route of Infection	Year of Infection	Estimated time of infection ² (years)	Sequence	Time between samples (months)	Clinical Stage	ART	Yeast load (copies/mL)	CD4+ Counts (cells/mm ³)	Genbank accession numbers
A	M	8	Guinea Bissau	Guinea Bissau	Blood Transfusion	1987	12	A1	60	AIDS	YES	NA	159	AJ344370
								B1	10	AIDS	YES	NA	48	AJ344371
								E1	10	AIDS	YES	NA	53	AJ344373
B	M	42	Guinea Bissau	Guinea Bissau	Heterosexual	Before 1988	>8	C1	24	ASYN	NO	450	457	AJ344382
								C2	47	ASYN	YES	NA	NA	AJ344383
								C4	40	ASYN	YES	NA	387	GG890216
								C5	3	ASYN	YES	NA	280	AY522984
C	F	44	Portugal	Portugal	Heterosexual	1993	16	C6	2	AIDS	YES	5700	156	GG890218
								C7	2	AIDS	YES	390	336	GG890219
								C8	10	ASYN	YES	470	149	GG890220
								C9	4	AIDS	YES	860	128	GG890221
D	F	53	Guinea Bissau	Guinea Bissau	Heterosexual	1988	9	D1	3	ASYN	YES	<100	429	GG890223
								D2	1	ASYN	YES	NA	242	GG890224
								D3	36	ASYN	YES	NA	630	AY522985
								D4	33	ASYN	NO	<200	610	AJ344385
E	F	29	Portugal	ND	Heterosexual	Before 2000	>5	E1	31	ASYN	NO	NA	1550	AJ344386
								F1	33	ASYN	NO	NA	NA	GG890227
								F3	59	ASYN	NO	NA	NA	GG890228
F	F	30	Angola	Portugal	Heterosexual	1988	16	F1	33	ASYN	NO	NA	NA	GG890229
								F3	59	ASYN	NO	NA	NA	GG890230
G	M	23	Cape Vert	Cape Vert	Heterosexual	Before 1992	>7	G1	6	ASYN	NO	NA	407	AJ344411
								G2	6	ASYN	NO	NA	450	AJ344411
H	F	21	Guinea Bissau	Guinea Bissau	Heterosexual	Before 2000	>4	H1	26	ASYN	YES	<200	427	AJ344424
								H2	23	ASYN	YES	NA	NA	AY522983
								H3	23	ASYN	YES	NA	NA	GG890227
I	F	23	Portugal	Portugal	Heterosexual	1999*	>2	I1	6	ASYN	NO	NA	NA	AJ344397
								I2	17	ASYN	NO	<200	NA	AY522986
								I3	17	ASYN	NO	<200	288	GG890228
J	M	48	Guinea Bissau	Guinea Bissau	Heterosexual	Before 1988	>20	J1	59	ASYN	NO	310	623	GG890229
								J2	4	ASYN	NO	390	599	GG890230
								J4	8	ASYN	NO	<50	570	GG890231
								J5	8	ASYN	YES	<50	NA	GG890232
K	M	55	Portugal	Africa	Heterosexual	1965	38	K1	48	ASYN	NO	NA	1050	D2460116
								K2	48	ASYN	NO	NA	1050	D2460116
L	F	23	Cape Vert	NA	Heterosexual	2002*	>2	L1	39	ASYN	NO	NA	1050	GG890233
								L2	39	ASYN	NO	NA	NA	GG890234
M	M	57	Guinea Bissau	Guinea Bissau	Blood Transfusion	1974	34	M1	4	ASYN	YES	<50	271	GG890235
								M2	11	AIDS	YES	8500	148	GG890236
N	F	NA	African	NA	Heterosexual	2000*	>2	N1	22	ASYN	YES	NA	NA	AY522989
								N2	22	ASYN	YES	NA	NA	AY522991
O	F	25	Guinea Bissau	NA	Heterosexual	2002*	>2	O1	33	ASYN	YES	NA	269	GG890238
								O2	33	ASYN	YES	NA	NA	GG890239
P	F	27	Guinea Bissau	NA	Heterosexual	2001*	>5	P1	64	ASYN	NO	NA	NA	GG890241
								P2	64	ASYN	NO	NA	NA	GG890241
Q	F	32	NA	NA	Heterosexual	1999*	>2	Q1	18	ASYN	YES	NA	NA	GG890243
								Q2	18	ASYN	YES	NA	NA	GG890243

F – female; M – male; ASYN – asymptomatic; ART – Antiretroviral therapy; NA – not available; 1 – age of patient at the time of the year of infection was unknown; 2 – When the year of infection was unknown, it was replaced by diagnostic's year; 3 – Time of infection calculated by the difference between the estimated date of infection and the time of the last sample collection.

Materials and Methods

HIV-2 Sample Collection: HIV-2 infected subjects were selected based on available biological samples, collected in several time points, between 1994 and 2009 and corresponding to different clinical stages of infection.

Amplification and Sequencing of HIV-2 *nef* gene: HIV-2 proviral DNA was extracted from PBMC with QIAamp DNA Mini Kit (QIAGEN) according to manufacturer's instructions. Nested PCR amplification of the *nef* gene was performed using outer and inner primers and the reaction conditions described in Pádua *et al.*, 2003 [8]. The PCR products were purified by QIAquick PCR Purification Kit (QIAGEN) and sequenced in both strands by using the inner primers, the BigDye Terminator Cycle Sequencing kit (Applied Biosystems) and an automated capillary sequencer (ABI PRISM 310, Applied Biosystems). Sequence consensus corresponding to each sample was generated using BioEdit 7.0.9.0 [9], Consensus Maker [10] and ClustalX 2.0.10 [11].

Sequence Analysis: MEGA computer package 4.0.2 [12] was used for phylogenetic analysis and distance calculations, aligned sequences were trimmed to remove gaps. The tree was constructed by Neighbor-joining method, supported by 1000 bootstrap replicates using SIMM239 reference sequence as outgroup.

Hypermutation analysis was performed by Hypermut 2.0 [10]. The D-S-DN ratio was calculated using SNAP program [10] in accordance with the method of Nei and Gojobori, 1986 [13] and incorporating a statistical test developed by Ota and Nei, 1994 [14]. Positively selected sites were identified in *nef* sequences using Bayesian M8 model and likelihood ratio test for statistical analysis [15]. Both analyses were performed at Selector server [16].

Statistical Evaluation: The SPSS 17.0.0 was used with a level of significance of 5%. Mann-Whitney test was performed to compare means and medians between unpaired variables and Fisher bilateral exact test to study the association between variables. The Pearson parametric correlation was used for association between two quantitative variables. Confidence intervals of percentages were also calculated.

Evolution of HIV-2 *Nef* Sequences and Variation of Functional Motifs

The residue M₂₀ and the PxxP motif in Vif terminal region described in HIV-1 infection, were absent in HIV-2 sequences analyzed. However, the MGxxx₅ motif is 100% conserved (Figure 3).

While several motifs (DDDD₃₉, RR₁₃₇ and DD₂₀₅) and also residues (G₁₂₇, I₁₄₁ and L₁₄₂) remained fairly conserved, others sequences (YSRF₃₉, LRAR₂₁, PxxP₁₀₁, EE₁₈₅, LL₁₉₃) revealed intra and inter-individuals amino acid changes (Figure 3).

The di-acidic motif described as conserved in HIV-1 sequences, was identified as EG₁₈₅ configuration for the majority of HIV-2 studied cases. Nevertheless, the EE₁₈₅ configuration was also observed and statistically associated with the symptomatic stage of infection (Fisher's bilateral test, p=0.002) (Figure 3).

Disruption of the minimal core PxxPLR motif was observed in 11 sequences exclusively related to asymptomatic individuals (Fisher's bilateral test, p=0.021). The variation towards the complete configuration which is typically observed in HIV-1 sequences was identified in HIV-2 symptomatic patients. Reconstruction to a complete tetra-proline motif was observed in patient "A" after 12 years in AIDS clinical stage, and also observed in patient "J" during the switch of his clinical status to a symptomatic phase of infection. Nevertheless, this complete motif was also observed in only one asymptomatic individual but with 16 years of HIV-2 infection (Individual F) (Figure 3).

For patient C, with 9 samples studied during a follow up period of 146 months, it was observed a positive correlation among divergence and the time between samples collection (Pearson's correlation, r=0.4, p=0.016) (Figure 4).

Data revealed the existence of a negative selective pressure in HIV-2 *nef* gene throughout infection. However, 5 individuals (C, F, H, I and M) exhibited codons under positive selective pressure in the *nef* sequences.




Figure 3 – Comparison of *Nef* functional motifs present in HIV-1 and studied HIV-2 *nef* sequences. 1 – Myristoylation signal, 2 – Methionine residue, 3 – alpha-helix, 4 – Tyr-based sorting signal, 5 – Acidic cluster, 6 – Tetra-proline motif, 7 – G residue, 8 – Pak association motif, 9 – Isoleucine residue, 10 – Leucine residue, 11 – Di-acidic motif, 12 – Di-leucine motif, 13 – DD motif, 14 – Minimal proline motif




Figure 1 – Phylogenetic tree based on 48 HIV-2 *nef* sequences (761 nucleotides) derived from 17 infected individuals. It was used reference sequences from subtype A, B, G and U retrieved from HIV Los Alamos database. SIMM239 *nef* sequence was used as outgroup and the nucleotide distances were estimated with Kimura's two-parameter model. Bootstrap values above 70% (of 1000 resamplings) are indicated. Each individual studied has a different color mark.




Figure 2 – Alignment of *Nef* sequences derived from 17 HIV-2 infected individuals. The multiple alignment sequences have been compared to the general consensus (C), the asymptomatic (CA) and the symptomatic consensus (CS). The capital letters corresponds to total conservation, lowercase letters represents partial conservation and 7 indicate highly variable amino acid positions. Dots indicate amino acid identity, dashes indicate sequence gaps. Functional motifs are shaded in blue.




Figure 4 – Positive correlation among divergence and the time between samples collection observed in patient C (Pearson's correlation, r=0.4, p=0.016) (Figure 4).

References

1. Instituto Nacional de Saúde Doutor Ricardo Jorge. Anuário de Doenças Infecciosas e Parasitárias em Portugal. Lisboa: INSA; 2009.
2. Instituto Nacional de Saúde Doutor Ricardo Jorge. Anuário de Doenças Infecciosas e Parasitárias em Portugal. Lisboa: INSA; 2009.
3. Instituto Nacional de Saúde Doutor Ricardo Jorge. Anuário de Doenças Infecciosas e Parasitárias em Portugal. Lisboa: INSA; 2009.
4. Instituto Nacional de Saúde Doutor Ricardo Jorge. Anuário de Doenças Infecciosas e Parasitárias em Portugal. Lisboa: INSA; 2009.
5. Instituto Nacional de Saúde Doutor Ricardo Jorge. Anuário de Doenças Infecciosas e Parasitárias em Portugal. Lisboa: INSA; 2009.
6. Instituto Nacional de Saúde Doutor Ricardo Jorge. Anuário de Doenças Infecciosas e Parasitárias em Portugal. Lisboa: INSA; 2009.
7. Instituto Nacional de Saúde Doutor Ricardo Jorge. Anuário de Doenças Infecciosas e Parasitárias em Portugal. Lisboa: INSA; 2009.
8. Pádua E, Feliciano H, Remédios M, et al. HIV-2 *nef* gene sequence variation and its association with clinical progression. *J Clin Microbiol*. 2003;41:1000-1005.
9. BioEdit. A user-friendly biological sequence alignment editor and analysis tool. *Bioinformatics*. 1998;14:95-98.
10. Consensus Maker. <http://www.fredonlinelab.com/consensus-maker/>
11. ClustalX. <http://www.ebi.ac.uk/Software/ClustalX/>
12. Molecular Evolutionary Genetics Analysis (MEGA) software. <http://www.megasoftware.net/>
13. Nei M, Gojobori T. Simple methods for calculating the number of nucleotide substitutions in the control region of mitochondrial DNA in humans and chimpanzees. *Mol Biol Evol*. 1986;3:416-426.
14. Ota T, Nei M. A statistical test for detecting positive selection at the molecular level. *Mol Biol Evol*. 1994;11:717-723.
15. Yang Z, Nielsen R. Codon-based methods for identifying positively selected sites. *Mol Biol Evol*. 2000;17:1031-1036.
16. Selector server. <http://www.selectorserver.com/>

Conclusions

These data suggested that throughout HIV-2 infection, the sequences and particular functional motifs evolve to specific configurations that were usually observed in HIV-1 infection. The existence of motifs within the *Nef* protein with similar functions potentially allowed some disruption without a complete loss of effects in viral process. A greater proportion of conserved *Nef* sequences at the AIDS stage was observed in this study. Even though it seems necessary to maintain a functional *Nef* protein throughout infection, sequences altered in earlier stages of infection and potentially critical for the *Nef* function in vivo, may contribute at some level to a different pattern in viral pathogenesis and disease progression. To support this findings a continue follow up of the HIV-2 infected patients and further studies on *Nef* expression will be taken into account.